Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a type of drug called a monoclonal antibody that has been studied in other types of cancers, such as kidney and colon. This monoclonal antibody is directed against the epidermal growth factor receptor (EGFR). EGFR has been found on the majority of head and neck cancer cells. By blocking EGFR, this monoclonal antibody may inhibit the growth of head and neck cancer cells.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborators: Amgen; Brigham and Women's Hospital
• Treatments: Antibodies, Monoclonal; Carboplatin; Docetaxel; Fluorouracil; Paclitaxel; Panitumumab

Criteria

Inclusion Criteria:

• Histologically or cytologically proven squamous cell carcinoma of the head and neck or its variants (such as basaloid squamous cell carcinoma, undifferentiated carcinoma, or adenosquamous cell carcinoma). Primary tumor sites eligible include: nasopharynx, oral cavity, oropharynx, hypopharynx, larynx or unknown primary SCCHN

• Stage III or IV disease, without evidence of distant metastasis, according to American Joint Committee on Cancer

• Measurable disease, according to RECIST.

• No prior chemotherapy, radiotherapy or attempted complete resection of the SCCHN. Diagnostic biopsy, including excisional nodal biopsy and/or tonsillectomy is allowed if the subject has measurable disease at the time of enrollment

• 18 years of age or older

• ECOG Performance Status of 0 or 1

• No active alcohol addiction or other condition that, in the opinion of the study investigators, would interfere with the subject's ability to comply with the treatment plan

• Adequate hepatic and renal function

• Women of childbearing potential must have a negative pregnancy test within 2 weeks of study entry.

Exclusion Criteria:

• Pregnant or breast feeding women

• Symptomatic peripheral neuropathy of grade 2 or higher by NCI CTCAEv3.0

• Grade 3 or more hearing loss

• History of other malignancy within the previous 5 years, except for nonmelanoma skin cancer, carcinoma in situ of the cervix, bladder or head and neck

• Prior radiation to head and neck

• Other serious illness or medical conditions

• Patients who experienced an involuntary weight loss of more than 20% of their body weight in the 2 months preceding study entry

• Concurrent treatment with any other anticancer therapy

• Prior therapy which affects or targets the ErbB pathway, including any inhibitors of EGFR and ErbB2

• Participation in an investigational drug trial within 30 days of study entry